TrkB-Pathway Prostate Panel (BDNF/TrkB/p75 IHC tissue test)
A tissue test that scores prostate cancer to see if it is driven by a specific growth protein.
A standardized immunohistochemistry panel measuring BDNF, TrkB, and p75 in prostate biopsy or prostatectomy tissue, returning a 'TrkB-pathway activity score' that flags prostate cancers running a neurotrophin-driven growth program for closer management and pathway-targeted trial referral.
Concept
A three-marker immunohistochemistry (IHC) panel — BDNF, TrkB, and p75 — for prostate needle-biopsy and radical-prostatectomy tissue, sold as a staining kit plus scoring software to hospital and reference pathology labs, or run as a central-lab developed test. Each specimen receives a TrkB-Pathway Activity Score (staining intensity × percent positive cells for BDNF and TrkB), with p75 reported as present or absent.
The clinical wedge is a single, measurable signature: BDNF-high / TrkB-high / p75-null. In the source study this combination marked diseased prostate tissue (cancer and hyperplasia) while normal peripheral zone showed only low neurotrophin expression — and the BDNF/TrkB axis is documented across tumor types to drive proliferation, metastasis, and drug resistance. The report gives urologists an adjunct to Gleason grade and PSA that (1) flags tumors with a neurotrophin-driven growth program and loss of the pro-apoptotic p75 receptor (an apoptotic-escape phenotype), and (2) identifies patients whose tumors are plausible candidates for BDNF/TrkB-pathway trials — a referral path that now exists given clinically available TRK inhibitors.
Right-sized commercialization: the 40-subject study establishes the expression differential, not outcome prediction. The first product milestone is retrospective validation on archived, outcome-linked prostatectomy specimens (biobanks hold thousands), with clinical launch contingent on the score adding independent prognostic information.
Why now
- The new immunohistochemical study of 40 subjects (16 prostate cancers, 20 BPH, 4 normal cadaveric peripheral-zone samples) found high BDNF and TrkB expression in prostate cancer and BPH, no detectable p75 in any sample, and only low NGF/NT3/TrkA/TrkC — a clean signature that ordinary clinical IHC platforms can measure [0].
- A review of the BDNF/TrkB pathway in tumors shows this signaling axis promotes tumor-cell proliferation, survival, metastasis, and treatment resistance [1], so high tumor TrkB is mechanistically interpretable as an aggressiveness/resistance marker rather than an incidental stain.
- TrkB is already treated as a disease-relevant kinase target in human solid tumors such as glioma [4], and small-molecule TRK inhibitors are a clinically maturing drug class [3] — meaning reagents, pathology scoring experience, and a downstream trial/therapy landscape for pathway-positive patients already exist.
Written by GLM · 8 Oct 2026
AI assessment
A focused IHC diagnostic panel targeting a specific neurotrophin signature to identify a subset of prostate cancers eligible for TRK-inhibitor therapies.
- Evidence strength 3/5
- The core signature is based on a very small study (40 subjects), which is insufficient for clinical validation but provides a clear biological hypothesis.
- Market pull 4/5
- There is a clear clinical need for better prostate cancer stratification and a direct path to value via referral to existing TRK-inhibitor clinical trials.
- Novelty & moat 5/5
- The idea applies a specific neurotrophin-axis signature to prostate cancer diagnostics, which is distinct from the general mutational or metabolic panels in the catalog.
- Feasibility 5/5
- IHC is a mature technology; building a staining kit and scoring software for known proteins is a low-technical-risk MVP.
- Wedge clarity 4/5
- The 'BDNF-high / TrkB-high / p75-null' signature is a sharp, specific entry point for trial eligibility screening.
- Simplicity / focus 5/5
- The product is a single, well-defined diagnostic panel rather than an over-scoped platform.
Scored by Gemma 4 · 8 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Myriad Geneticscompany
Already sells Prolaris, a prostate-cancer prognostic test, to urologists through its CLIA lab; a tissue IHC TrkB panel is a natural adjacent product for the same customer base and sales channel.
Supplies IHC staining platforms and assays to pathology labs worldwide; it could manufacture and distribute the BDNF/TrkB/p75 panel as a new prostate assay on installed instruments.
- Exact Sciencescompany
Offers the Oncotype DX Genomic Prostate Score; adding a protein-level pathway assay would diversify its prostate portfolio and use its existing urology commercial infrastructure.
- Agilent Technologies (Dako)company
A major vendor of IHC reagents and pathology platforms; a validated three-marker prostate panel expands its assay menu with limited development risk.
- Prostate Cancer Foundationorganization
Funds translational prostate-cancer biomarker research; a defined, validation-ready IHC signature with a clear retrospective-validation protocol is exactly the kind of concrete project its research programs support.
Research it builds on
- Oncology ReportsBRONZETTI, Elena, ARTICO, Marco, FELICI, Laura Maria et al. · 2026 · 211 citationsAll ideas from this paper →
- Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancersTingting Jiang, Guan Wang, Yao Liu et al. · 2020 · 147 citationsAll ideas from this paper →
- Targeting the BDNF/TrkB pathway for the treatment of tumors (Review)Lingbin Meng, Baoqiong Liu, Rui Ji et al. · 2018 · 77 citationsAll ideas from this paper →
- Targeting tyrosine receptor kinase B in gliomasKelly V. Pinheiro, Camila Fernanda da Silveira Alves, Marienela Buendia et al. · 2016 · 20 citationsAll ideas from this paper →